Lupin Pharmaceuticals was established in 1968 by Desh Bandhu Gupta and focused majorly on Products and services like Brand Formulations, Generics, APIs, Biotechnology and Drug discovery.
It is the second largest Pharma Company in India with a market capitalization of about INR 770 billion. It is a US owned subsidiary of Lupin Limited and has shown tremendous growth potential in therapeutic areas like Asthma, Oncology, Cardiology and Diabetology.
The company is headquartered in Mumbai in the state of Maharashtra.
The company is named after Lupin flower for the inherent qualities that flower possess. As the flower grows it nourishes the soil. In the same way Lupin has been nourishing the lives of people since its inception.
The company gained much recognition when it became world’s largest manufacturers of TB drugs. The company is succeeding globally with its strong foothold in advanced markets due to its effective and efficient STP (Segmentation, Targeting and Positioning) of its products. It is also one of the top companies in South Africa, Japan and US market.
Lupin has manufacturing facilities in five cities in India and also one site is in Thailand which is US FDA and WHO approved. It also has state-of-the art research facilities in India which work in collaboration with global companies and laboratories. The R&D expenses amounted to 1600 crores which shows that R&D is the driving force in the discovery of new drugs and technology led innovation.
Lupin Pharmaceuticals is also helping the nation by its CSR activities. Its aim is to help rural people by its rural development projects which started in Bharatpur district of Rajasthan. Currently more than million people are being benefitted by its CSR activities.